vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and RANGE RESOURCES CORP (RRC). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $786.9M, roughly 1.5× RANGE RESOURCES CORP). RANGE RESOURCES CORP runs the higher net margin — 22.8% vs 17.0%, a 5.8% gap on every dollar of revenue. On growth, RANGE RESOURCES CORP posted the faster year-over-year revenue change (18.0% vs 10.1%). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 14.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Range Resources Corporation is a natural gas exploration and production company, the headquartered is in Fort Worth, Texas. It operates in the Marcellus Formation, where it is the largest land owners.
JAZZ vs RRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $786.9M |
| Net Profit | $203.5M | $179.1M |
| Gross Margin | — | 94.5% |
| Operating Margin | 21.2% | — |
| Net Margin | 17.0% | 22.8% |
| Revenue YoY | 10.1% | 18.0% |
| Net Profit YoY | 6.5% | 88.8% |
| EPS (diluted) | $3.34 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $786.9M | ||
| Q3 25 | $1.1B | $655.3M | ||
| Q2 25 | $1.0B | $699.6M | ||
| Q1 25 | $897.8M | $846.3M | ||
| Q4 24 | $1.1B | $667.0M | ||
| Q3 24 | $1.1B | $567.9M | ||
| Q2 24 | $1.0B | $513.2M | ||
| Q1 24 | $902.0M | $598.8M |
| Q4 25 | $203.5M | $179.1M | ||
| Q3 25 | $251.4M | $144.3M | ||
| Q2 25 | $-718.5M | $237.6M | ||
| Q1 25 | $-92.5M | $97.1M | ||
| Q4 24 | $191.1M | $94.8M | ||
| Q3 24 | $215.1M | $50.7M | ||
| Q2 24 | $168.6M | $28.7M | ||
| Q1 24 | $-14.6M | $92.1M |
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
| Q4 25 | 21.2% | — | ||
| Q3 25 | 5.1% | — | ||
| Q2 25 | -65.6% | — | ||
| Q1 25 | -6.2% | — | ||
| Q4 24 | 17.5% | — | ||
| Q3 24 | 24.7% | — | ||
| Q2 24 | 19.5% | — | ||
| Q1 24 | 7.3% | — |
| Q4 25 | 17.0% | 22.8% | ||
| Q3 25 | 22.3% | 22.0% | ||
| Q2 25 | -68.7% | 34.0% | ||
| Q1 25 | -10.3% | 11.5% | ||
| Q4 24 | 17.6% | 14.2% | ||
| Q3 24 | 20.4% | 8.9% | ||
| Q2 24 | 16.5% | 5.6% | ||
| Q1 24 | -1.6% | 15.4% |
| Q4 25 | $3.34 | $0.75 | ||
| Q3 25 | $4.08 | $0.60 | ||
| Q2 25 | $-11.74 | $0.99 | ||
| Q1 25 | $-1.52 | $0.40 | ||
| Q4 24 | $2.97 | $0.38 | ||
| Q3 24 | $3.42 | $0.21 | ||
| Q2 24 | $2.49 | $0.12 | ||
| Q1 24 | $-0.23 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $204.0K |
| Total DebtLower is stronger | $5.4B | $1.2B |
| Stockholders' EquityBook value | $4.3B | $4.3B |
| Total Assets | $11.7B | $7.4B |
| Debt / EquityLower = less leverage | 1.24× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $204.0K | ||
| Q3 25 | $1.3B | $175.0K | ||
| Q2 25 | $1.2B | $134.0K | ||
| Q1 25 | $1.9B | $344.6M | ||
| Q4 24 | $2.4B | $304.5M | ||
| Q3 24 | $2.2B | $277.4M | ||
| Q2 24 | $1.4B | $251.1M | ||
| Q1 24 | $1.4B | $343.1M |
| Q4 25 | $5.4B | $1.2B | ||
| Q3 25 | $5.4B | $1.2B | ||
| Q2 25 | $5.4B | $1.2B | ||
| Q1 25 | $5.4B | $1.7B | ||
| Q4 24 | $6.1B | $1.7B | ||
| Q3 24 | $6.1B | $1.7B | ||
| Q2 24 | $5.7B | $1.7B | ||
| Q1 24 | $5.7B | $1.8B |
| Q4 25 | $4.3B | $4.3B | ||
| Q3 25 | $4.0B | $4.2B | ||
| Q2 25 | $3.7B | $4.1B | ||
| Q1 25 | $4.2B | $3.9B | ||
| Q4 24 | $4.1B | $3.9B | ||
| Q3 24 | $4.2B | $3.9B | ||
| Q2 24 | $3.8B | $3.9B | ||
| Q1 24 | $3.7B | $3.8B |
| Q4 25 | $11.7B | $7.4B | ||
| Q3 25 | $11.4B | $7.2B | ||
| Q2 25 | $10.9B | $7.1B | ||
| Q1 25 | $11.5B | $7.4B | ||
| Q4 24 | $12.0B | $7.3B | ||
| Q3 24 | $12.3B | $7.2B | ||
| Q2 24 | $11.4B | $7.3B | ||
| Q1 24 | $11.3B | $7.4B |
| Q4 25 | 1.24× | 0.28× | ||
| Q3 25 | 1.35× | 0.29× | ||
| Q2 25 | 1.45× | 0.29× | ||
| Q1 25 | 1.29× | 0.43× | ||
| Q4 24 | 1.49× | 0.43× | ||
| Q3 24 | 1.47× | 0.44× | ||
| Q2 24 | 1.52× | 0.44× | ||
| Q1 24 | 1.54× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $257.5M |
| Free Cash FlowOCF − Capex | $345.8M | — |
| FCF MarginFCF / Revenue | 28.9% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.78× | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $257.5M | ||
| Q3 25 | $474.6M | $247.5M | ||
| Q2 25 | $88.9M | $336.2M | ||
| Q1 25 | $429.8M | $330.1M | ||
| Q4 24 | $398.6M | $217.9M | ||
| Q3 24 | $398.7M | $245.9M | ||
| Q2 24 | $331.4M | $148.8M | ||
| Q1 24 | $267.2M | $331.9M |
| Q4 25 | $345.8M | — | ||
| Q3 25 | $459.4M | — | ||
| Q2 25 | $75.9M | — | ||
| Q1 25 | $415.9M | — | ||
| Q4 24 | $385.3M | — | ||
| Q3 24 | $388.0M | — | ||
| Q2 24 | $324.3M | — | ||
| Q1 24 | $260.3M | — |
| Q4 25 | 28.9% | — | ||
| Q3 25 | 40.8% | — | ||
| Q2 25 | 7.3% | — | ||
| Q1 25 | 46.3% | — | ||
| Q4 24 | 35.4% | — | ||
| Q3 24 | 36.8% | — | ||
| Q2 24 | 31.7% | — | ||
| Q1 24 | 28.9% | — |
| Q4 25 | 1.4% | — | ||
| Q3 25 | 1.3% | — | ||
| Q2 25 | 1.2% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 0.7% | — | ||
| Q1 24 | 0.8% | — |
| Q4 25 | 1.78× | 1.44× | ||
| Q3 25 | 1.89× | 1.72× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | 2.09× | 2.30× | ||
| Q3 24 | 1.85× | 4.85× | ||
| Q2 24 | 1.97× | 5.18× | ||
| Q1 24 | — | 3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
